AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
MWN-AI** Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced a significant development on June 12, 2025, concerning the trading status of its common stock. The NYSE Regulation staff has lifted the trading suspension that had previously been imposed, indicating that AIM’s stock is now trading above the minimum price threshold and is no longer subject to delisting concerns. This decision allows AIM’s shares to resume trading on the NYSE American starting June 17, 2025, under the ticker symbol “AIM.”
AIM ImmunoTech, based in Ocala, Florida, is an immunotherapy-focused pharmaceutical company dedicated to developing treatments for various cancers, immune disorders, and viral diseases, including COVID-19. The company's lead investigational drug, Ampligen® (rintatolimod), is a first-of-its-kind treatment designed to stimulate the immune system and has shown promise in clinical trials targeting significant health challenges.
The announcement comes with a cautionary note emphasizing the forward-looking statements that accompany such significant news. The company reminds investors that numerous risks and uncertainties may affect the progress and approval of Ampligen as a therapeutic option. As with any clinical investigation, past successes do not guarantee future results, hence investors are urged to scrutinize the risk factors detailed in AIM’s recent filings with the U.S. Securities and Exchange Commission.
AIM ImmunoTech provides ongoing updates through multiple channels, including their official website and social media platforms, keeping investors informed about their research developments and corporate progress.
MWN-AI** Analysis
AIM ImmunoTech's recent announcement regarding the withdrawal of its delisting determination by NYSE Regulation and the subsequent lifting of its trading suspension is a critical turning point for the company. After a period of uncertainty, AIM is set to resume trading on the NYSE American under the ticker symbol "AIM" on June 17, 2025. This development underscores the company’s regained compliance with market regulations, specifically concerning price thresholds, which can instill investor confidence.
Investors should closely observe AIM's unique positioning within the immuno-pharma sector, particularly its lead product, Ampligen® (rintatolimod). As an investigational drug with potential applications against various cancers, immune disorders, and viral diseases—including treatments associated with COVID-19—Ampligen's success could drive significant revenue growth if it receives regulatory approval. However, it is crucial to approach this investment with a balanced perspective.
While the lifting of the trading suspension is a positive sign, investors must remain cautious. The healthcare and pharmaceutical sectors are highly volatile and can be influenced by factors such as clinical trial results, regulatory approvals, competition from other therapies, and broader market conditions. AIM has highlighted the inherent risks in its forward-looking statements, advising investors to thoroughly review these factors, which are detailed in their Form 10-K filings.
In conclusion, AIM ImmunoTech presents an intriguing investment opportunity for those who are willing to navigate the associated risks. As the stock resumes trading, investors should monitor clinical developments and market trends closely while maintaining a robust risk management strategy. The potential for Ampligen, combined with the restored trading status, could offer substantial upside, but proper diligence is essential before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American. The NYSE Regulation staff determined that the Company's common stock was now trading above the threshold of low selling price issues as further defined by Section 1003(f)(v) of the NYSE American Company Guide. AIM’s common stock is expected to resume trading on the NYSE American on Tuesday, June 17, 2025, under the symbol "AIM" and CUSIP 00901B303.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
What factors led to the lifting of the trading suspension for AIM ImmunoTech Inc. AIM and what changes contributed to the company trading above the NYSE American's low selling price threshold?
How does the resumption of trading for AIM ImmunoTech Inc. AIM on June 17, 2025, influence investor sentiment and the company's market performance compared to its previous trading history?
What updates can investors expect regarding the clinical trials of Ampligen ® (rintatolimod) for various cancers and diseases from AIM ImmunoTech Inc. AIM following their trading resumption?
Considering the forward-looking statements made by AIM ImmunoTech Inc. AIM, what specific risk factors should investors be aware of that could impact the potential approval process for Ampligen as a therapy?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
